The immune system is not a passive bystander in endometriosis — it is an active participant. Interleukin-1 alpha¹¹ Interleukin-1 alpha
IL-1α: a pro-inflammatory cytokine produced chiefly by macrophages and monocytes; signals through the IL-1 receptor to activate NF-κB and trigger downstream inflammatory cascades is one of the most consistently elevated cytokines in the peritoneal fluid of women with endometriosis. The gene encoding IL-1α, IL1A, resides on chromosome 2q14.1 and harbors a cluster of common variants that have emerged from multiple genetic association studies as replicated susceptibility factors for the disease. Among these, rs2856836 — located in the 3' untranslated region of the IL1A transcript — is one of eight IL1A locus SNPs shown to replicate across both European and Japanese populations.

The Mechanism

rs2856836 is a 3' UTR variant²² 3' UTR variant
variants in the 3' untranslated region can alter mRNA stability, translational efficiency, or microRNA binding sites, affecting how much protein the gene ultimately produces. It does not change the IL-1α amino acid sequence. On the plus (forward) strand the reference allele is A and the alternate allele is G; because IL1A is transcribed from the minus strand, published papers commonly describe this as a T/C variant in coding-strand notation (T=reference, C=risk). The G allele (plus strand) sits at position chr2:112,774,506 (GRCh38), 561 nucleotides into the 3' UTR of transcript NM_000575.5.

The functional consequence of this specific 3'UTR change has not been experimentally characterised in isolation. The broader IL1A endometriosis risk locus, however, has been functionally mapped in detail: expression quantitative trait locus (eQTL) analysis across ten tissue types³³ expression quantitative trait locus (eQTL) analysis across ten tissue types
Ochoa et al. 2025, Adv Sci; PMC12591210 shows that risk variants at the IL1A locus are associated with decreased IL1A expression, and that M2 peritoneal macrophages — the cell type that lines the peritoneal cavity and governs immune tolerance of ectopic endometrial tissue — are the primary germline risk mediators at this locus. The IL1A/IL1B cytokines scored the highest correlation with endometriosis risk across myeloid subgroups (Spearman r=0.59). In the endometriosis-affected peritoneal environment, dysregulated IL-1 signaling may impair macrophage-mediated clearance of refluxed endometrial cells — the critical gatekeeping step that, when disrupted, allows retrograde tissue to implant and establish ectopic lesions.

The Evidence

The first signal at the IL1A locus came from a genome-wide association meta-analysis in Japanese women⁴⁴ genome-wide association meta-analysis in Japanese women
Adachi et al. 2010, J Hum Genet; 696 cases + 825 controls in which four of the five top-ranked SNPs (P<10⁻⁵) clustered around IL1A, identifying it as a functional candidate gene. A follow-up study⁵⁵ follow-up study
Hata et al. 2013, J Hum Genet of 901 Japanese cases and controls confirmed rs2856836 as one of four significantly associated IL1A variants (P=0.0014), alongside the missense variant rs17561 (Ala114Ser, OR=1.91 in validation). Cross-ethnic replication came from a meta-analysis of 3,908 cases and 8,568 controls⁶⁶ meta-analysis of 3,908 cases and 8,568 controls
Sapkota et al. 2015, Hum Reprod; PMC4262465 spanning Australian, British, and Japanese cohorts, where all eight IL1A SNPs replicated at P<0.014 with concordant effect directions. For rs2856836 specifically, the meta-analysis yielded OR=1.09 (95% CI 1.02–1.16, P=7.15×10⁻³) across all endometriosis, and OR=1.12 (95% CI 1.04–1.22, P=4.29×10⁻³) for moderate-to-severe (grade B) disease.

A smaller population-specific case-control study in Iranian women⁷⁷ Iranian women
Badie et al. 2020, Gynecol Endocrinol; 105 cases, 102 controls found a stronger effect for the G allele (coding-strand C) — OR=2.2 (95% CI 1.4–3.6, P=0.001) — with TC and CC genotypes independently significant (OR=3.1 and OR=2.3 respectively). This larger per-allele estimate likely reflects the smaller study size and possible founder effects in the Iranian population rather than a qualitatively different genetic architecture.

No ClinVar classification exists for rs2856836. The association signal is consistent with a moderate-evidence risk factor: replicated across multiple ethnic groups with clear dose-response, plausible biological mechanism, but short of genome-wide significance and lacking direct functional characterisation of this specific variant.

Practical Actions

The central implication of carrying one or two copies of the G allele is a modestly elevated inflammatory predisposition toward endometriosis. The individual risk increment per G allele is small in absolute terms (OR ~1.09–1.12 per allele in the large meta-analysis), and this variant should be interpreted in the context of the broader IL1A locus and other endometriosis risk SNPs. Women carrying the G allele who experience dysmenorrhea, cyclic pelvic pain, deep dyspareunia, or unexplained infertility should not normalize these symptoms — earlier gynecological evaluation shortens the diagnostic delay that averages 7–10 years.

The inflammatory basis of this association suggests that strategies targeting pelvic inflammation may be particularly relevant: NSAIDs, which block prostaglandin synthesis downstream of IL-1 signaling, are first-line for endometriosis-associated pain. No supplement or dietary intervention has been shown to specifically modulate IL1A expression or activity in peritoneal macrophages. The management decision — including hormonal therapy, surgical evaluation, or fertility preservation — rests with a gynecologist.

Interactions

rs2856836 is in linkage disequilibrium⁸⁸ linkage disequilibrium
LD: the tendency of nearby variants to be inherited together on the same chromosomal segment with the other seven IL1A locus SNPs studied by Sapkota et al. (2015), including the genome-wide significant regulatory variant rs6542095 (OR=1.21 for moderate-to-severe endometriosis) and the missense variant rs17561 (Ala114Ser). These SNPs reside within a ~8 kb stretch of the IL1A gene. Carriers of risk alleles at multiple IL1A locus SNPs may accumulate greater susceptibility through haplotype effects, though the independent contribution of each variant has not been formally dissected. The functional eQTL evidence points to the entire locus region modulating IL1A expression in M2 peritoneal macrophages — the single causal variant within this cluster has not been definitively identified.

Every cell in your body is under constant immunological inspection. The key checkpoint is MHC class I antigen presentation¹¹ MHC class I antigen presentation
a process by which cells display short peptide fragments on their surface for surveillance by CD8+ cytotoxic T cells — abnormal peptides trigger immune attack, and the quality of that display depends critically on an upstream editing step: peptide trimming by ERAP1 (Endoplasmic Reticulum Aminopeptidase 1)²² ERAP1 (Endoplasmic Reticulum Aminopeptidase 1)
an enzyme that clips peptides to exactly the right length (8-10 amino acids) before they can bind MHC class I molecules and reach the cell surface.

The rs30187 K528R variant changes a single amino acid in ERAP1's hinge region — and that single change fundamentally alters the enzyme's activity. The result is a miscalibrated peptide-trimming machine that shifts what your immune system sees and, in specific HLA backgrounds, increases the risk of two well-characterized autoimmune conditions: ankylosing spondylitis and psoriasis.

The Mechanism

ERAP1 acts as a molecular ruler³³ molecular ruler
the enzyme has a substrate-binding pocket that physically measures peptide length; when the peptide fits optimally, ERAP1 clips one amino acid and releases the peptide for loading onto MHC class I molecules. The enzyme cycles between an open (inactive) and closed (active) conformation. Lys528 (the common C-allele residue) sits at the hinge region that governs this conformational switch — it facilitates efficient transition to the closed, catalytically active state.

The K528R substitution (T allele) replaces lysine with arginine at position 528. Despite the chemical similarity, this change alters the kinetics of the open-to-closed transition, producing a hypofunctional enzyme⁴⁴ hypofunctional enzyme
an ERAP1 variant that trims peptides more slowly and incompletely than the common form. In biochemical assays, the K528R variant stalls at the 11-mer peptide stage — it can begin trimming but cannot efficiently complete the process to generate optimal 8-9 mer peptides. This means the T-allele ERAP1 produces a different peptide repertoire than the common enzyme: more long peptides that cannot bind MHC class I, and fewer optimal-length peptides that can.

The clinical consequence of this altered peptide landscape depends entirely on which HLA class I molecules are present in a given individual. This is why rs30187 exhibits strict epistasis⁵⁵ epistasis
a genetic interaction where the effect of one variant is entirely conditional on the genotype at a second locus with both HLA-B27 (in ankylosing spondylitis) and HLA-C*06:02 (in psoriasis).

The Evidence

Ankylosing Spondylitis: The foundational paper — a landmark GWAS meta-analysis published in Nature Genetics in 2011⁶⁶ landmark GWAS meta-analysis published in Nature Genetics in 2011
Evans et al., WTCCC2 consortium, 3,023 AS cases and 8,779 controls with replication in 2,871 cases and 9,087 controls — established that ERAP1 rs30187 is the single most functionally important coding variant in ERAP1 for AS susceptibility. The association follows strict HLA-B27 epistasis: ERAP1 variants were significantly associated with AS only in HLA-B27–positive individuals (combined P=7.3×10⁻⁶ for interaction), with no detectable association in HLA-B27–negative patients. HLA-B27–positive individuals homozygous for the protective C allele at rs30187 had approximately 3-4 times lower AS risk than HLA-B27–positive individuals carrying T-allele risk genotypes.

An updated meta-analysis incorporating 19,902 AS patients and 39,750 controls⁷⁷ updated meta-analysis incorporating 19,902 AS patients and 39,750 controls
Tian et al. 2015 confirmed the overall association (OR=1.255, 95% CI: 1.147-1.373, P=8.0×10⁻⁸), with the effect strongest in European populations (OR=1.283, 95% CI: 1.237-1.331, P<1.0×10⁻⁹).

Psoriasis: In psoriasis, rs30187 shows a more complex and bidirectional epistasis with HLA-C*06:02. A Polish cohort study⁸⁸ Polish cohort study
Szczerkowska-Dobosz et al. 2018, examining ERAP1/ERAP2 haplotypes stratified by HLA-C*06:02 status and disease onset showed that the T allele increases psoriasis risk in HLA-C*06:02 carriers (particularly late-onset disease) but is protective when HLA-C*06:02 is absent. This paradoxical direction-switching is a hallmark of epistatic interactions and underscores that the biological effect of K528R is entirely context-dependent.

A meta-analysis of nine case-control studies⁹⁹ meta-analysis of nine case-control studies
Wu et al. 2021, 4,858 psoriasis cases and 10,542 healthy controls confirmed the overall positive association (T vs C: OR=1.23, 95% CI: 1.15-1.32, P<0.00001), averaging across HLA backgrounds.

Functional validation: The mechanistic basis was confirmed by a functional study of naturally occurring ERAP1 haplotypes¹⁰¹⁰ functional study of naturally occurring ERAP1 haplotypes
Evnouchidou et al. 2013, PMC3785127 — comparative biochemical characterization of 10 ERAP1 haplotypes using diverse peptide substrates. The K528R variant consistently produced a hypofunctional enzyme across multiple substrates, generating incomplete trimming products rather than optimal 8-9 mer peptides. This directly demonstrates how the variant reshapes the peptide repertoire available for MHC class I loading.

Practical Implications

The T allele at rs30187 reduces ERAP1's peptide-editing efficiency. On its own, this is unlikely to cause disease — the altered peptide repertoire only becomes clinically meaningful when a specific HLA class I allele is present to present those aberrant or deficient peptides to the immune system.

If you carry the T allele and also carry HLA-B27 (not yet tested by GeneOps), your risk of ankylosing spondylitis is substantially elevated above the HLA-B27-only baseline. If you carry the T allele and also carry HLA-C*06:02 (check rs12191877), your risk of psoriasis is increased compared to HLA-C*06:02 carriers with the CC genotype.

Ankylosing spondylitis is a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints. It typically begins in young adulthood with morning back stiffness that improves with activity. Early diagnosis and appropriate treatment (NSAIDs, biologics targeting TNF or IL-17/IL-23) can prevent irreversible spinal fusion and maintain mobility.

Interactions

ERAP1 rs30187 × HLA-B27: Ankylosing Spondylitis Epistasis

The epistatic interaction between rs30187 and HLA-B27 in AS is one of the strongest documented gene-gene interactions in complex disease genetics. HLA-B27 presents a peptide repertoire that depends heavily on ERAP1's trimming output. The K528R variant changes which peptides are available, altering self-peptide presentation in a way that — in HLA-B27 carriers — tips the balance toward autoreactive immune activation. This interaction argues that the pathogenic mechanism of HLA-B27 in AS is fundamentally peptide-presentation-dependent.

This interaction is a candidate for compound action documentation. The relevant genotypes are: - rs30187 CT or TT (ERAP1 K528R risk allele present) combined with HLA-B27 positive status Combined recommendation: heightened AS surveillance, early rheumatological assessment for inflammatory back pain, and discussion of anti-inflammatory prophylaxis.

ERAP1 rs30187 × HLA-C*06:02 (rs12191877): Psoriasis Epistasis

The bidirectional epistasis with HLA-C*06:02 mirrors the psoriasis mechanism of the sibling variant rs27524. Where rs27524 alters ERAP1 expression levels, rs30187 alters ERAP1 catalytic efficiency — both ultimately modify the density and identity of peptides presented by HLA-C*06:02 on melanocytes. In HLA-C*06:02 carriers, the T allele's hypofunctional enzyme generates a different ADAMTSL5 peptide profile, contributing to psoriatic autoimmunity.

ERAP1 rs30187 × ERAP1 rs27524: Same-gene compound effect

rs30187 (K528R, coding missense) and rs27524 (intronic eQTL) affect ERAP1 through orthogonal mechanisms — one changes the enzyme's activity, the other changes its expression level. They co-occur on different haplotypes. The naturally occurring ERAP1 haplotype system (Hap1-Hap10) captures both variants together. Individuals inheriting risk haplotypes at both positions will have both more ERAP1 protein and less efficient ERAP1 protein — creating a complex net effect that varies by haplotype combination.

Von Willebrand factor (VWF) is the molecular glue of hemostasis — a large plasma protein that tethers platelets to damaged blood vessel walls and serves as the carrier and protector of coagulation Factor VIII (FVIII). The rs33978901 variant introduces a single amino acid change, replacing arginine with glutamine at position 924¹¹ replacing arginine with glutamine at position 924
p.Arg924Gln, encoded by c.2771G>A in the VWF coding sequence; the gene lies on the minus strand, so the plus-strand T allele corresponds to the coding-strand A allele. Unlike the dramatic pathogenic mutations in classical von Willebrand disease, this variant acts as a subtle modifier: in most carriers it causes no clinical problem, but in the wrong context — especially blood group O — it can push already-low VWF levels into a range that warrants medical attention.

The Mechanism

In vitro expression studies of recombinant p.R924Q VWF²² In vitro expression studies of recombinant p.R924Q VWF
Hickson et al. tested the variant protein in cell culture: no effect on VWF secretion, multimer structure, or FVIII binding was found showed no detectable functional defect. This means R924Q likely does not impair VWF protein directly but instead travels on a haplotype — a block of inherited variants³³ haplotype — a block of inherited variants
A haplotype is a set of alleles inherited together as a unit; the R924Q allele appears to tag a chromosomal background that is associated with reduced VWF production associated with lower VWF output. The biological mechanism is therefore quantitative (reduced VWF levels) rather than qualitative (abnormal protein structure or function).

The ABO blood group⁴⁴ ABO blood group
Encoded by the ABO gene on chromosome 9; the H antigen added to VWF by non-O blood groups increases its half-life and plasma concentration by protecting it from clearance independently controls VWF levels: blood group O individuals have VWF concentrations 25-35% lower⁵⁵ 25-35% lower
Consistently documented across multiple population studies; the mechanism involves reduced glycosylation protecting VWF from ADAMTS13 cleavage and macrophage clearance than non-O individuals. When R924Q-associated reduced production overlaps with blood group O's reduced half-life, the combined effect explains up to 35% of VWF variance⁶⁶ the combined effect explains up to 35% of VWF variance
Versus ~10% for the variant alone in controls not stratified by blood group — a clinically meaningful amplification.

The Evidence

The definitive study is Hickson et al. 2010⁷⁷ Hickson et al. 2010
Journal of Thrombosis and Haemostasis; 1,115 healthy controls and 148 von Willebrand disease index cases genotyped for c.2771G>A. Among 148 VWD index cases, the variant appeared in six; five of those six carried at least one additional VWF pathogenic mutation, indicating R924Q rarely causes VWD on its own but frequently appears as a co-factor. Among healthy controls, 35 heterozygous carriers were identified. Crucially, variance in VWF and FVIII levels attributable to the variant jumped from 10% overall to 35% in blood group O carriers — demonstrating strong epistatic amplification.

ClinVar (VCV000100240) reflects this nuanced picture: across 11 contributing submissions, classifications range from benign to uncertain significance, with no pathogenic calls. Major clinical laboratories (Mayo Clinic, ARUP, Quest Diagnostics) classify it as benign or likely benign in isolation. The variant's clinical relevance is context-dependent, not intrinsic.

Population frequency is low and strongly European-enriched: the T allele occurs at ~2.2% in Europeans and under 0.4% in African and South Asian populations, with near-absence in East Asians. This ancestry skew is consistent with a European founder haplotype.

Practical Actions

For most carriers, the variant is a monitoring signal rather than an emergency. The key practical step is baseline VWF antigen and FVIII activity measurement — this tells you whether levels are in the range where the variant is functionally relevant (typically VWF:Ag below 50 IU/dL or FVIII activity below 50%). If levels are normal, no further action is needed. If they are low-normal (50-100 IU/dL), tracking them is useful since acquired stressors (surgery, pregnancy, illness) can temporarily suppress VWF further. Carriers who also have blood group O should have this combination specifically noted, as the dual effect increases the probability that levels are measurably reduced.

Carriers contemplating surgery, tooth extraction, childbirth, or procedures involving significant bleeding risk should disclose this variant and have VWF/FVIII checked beforehand so that a hematologist can determine whether desmopressin (DDAVP) or VWF concentrate prophylaxis is warranted.

Interactions

The most clinically significant interaction is with ABO blood group O (rs505922 and related ABO loci). Blood group O reduces VWF levels 25-35% independently; the R924Q haplotype adds a further reduction, and together they account for up to 35% of VWF variance in carriers. This combination warrants specific clinical attention.

Any second pathogenic VWF variant — such as those causing type 1 or type 2 VWD — compounds with R924Q additively. In the Hickson cohort, 5 of 6 R924Q-carrying VWD cases had an additional VWF mutation, suggesting R924Q functions as a disease modifier that amplifies the effect of a primary mutation rather than a standalone cause.

The angiotensinogen gene (AGT) sits at the top of the renin-angiotensin-aldosterone system (RAAS), the body's primary hormonal axis for controlling blood pressure and fluid balance. Angiotensinogen is the sole precursor substrate for all angiotensin peptides¹¹ Angiotensinogen is the sole precursor substrate for all angiotensin peptides
renin cleaves AGT to produce angiotensin I, which ACE converts to the vasoconstrictor angiotensin II. During pregnancy, RAAS activity is tightly regulated: the system must expand blood volume to support the growing fetus while preventing excessive vasoconstriction that can compromise placental perfusion. When this balance fails, the result is gestational hypertension or preeclampsia — a condition affecting 3–5% of pregnancies and responsible for roughly 14% of maternal deaths worldwide.

The rs3889728 variant lies within an intron of AGT on chromosome 1 (GRCh38 position 230,713,085). The AGT gene runs on the minus strand, so the T allele in genome files corresponds to an A on the coding strand — the allele designation sometimes used in older papers. This variant has been incorporated into a diastolic blood pressure prediction model alongside two other SNPs (rs5193 and rs7305099) in a Han Chinese cohort study, suggesting it tags a regulatory region that modulates AGT expression or splicing in contexts relevant to blood pressure control.

The Mechanism

As an intron variant, rs3889728 does not alter the AGT protein directly. Its effect is likely mediated through a regulatory element²² regulatory element
intronic enhancers, silencers, or splice-branch-point sequences that influence how much mRNA is produced and how efficiently it is processed embedded within the intron. Elevated AGT levels (whether from coding variants or regulatory changes) increase angiotensin II production, raising vascular tone and sodium retention. In pregnancy, this has particular consequences: the maternal vascular system must dilate substantially to accommodate increased cardiac output, and any genetic factor that tips RAAS toward excess activation can impair the spiral artery remodeling that supplies the placenta.

The preeclampsia connection to AGT is well-established at the gene level. The most-studied AGT variant, M235T (rs699), encodes a threonine at position 235 that increases AGT plasma concentrations by approximately 20% in TT homozygotes compared to MM individuals. A large meta-analysis found TT homozygotes have approximately 61% higher odds of preeclampsia Lin et al. 2012, 31 studies, 2,555 cases³³ Lin et al. 2012, 31 studies, 2,555 cases
Angiotensinogen gene M235T and T174M polymorphisms and susceptibility of pre-eclampsia: a meta-analysis. Ann Hum Genet. The rs3889728 variant may influence AGT expression through a parallel intronic regulatory mechanism, making it a biologically plausible though less-studied contributor to this same pathway.

The Evidence

Direct evidence for rs3889728 specifically comes from a cross-sectional study of 965 Northern Han Chinese adults by Li et al. 2019⁴⁴ Li et al. 2019
A Prediction Model of Essential Hypertension Based on Genetic and Environmental Risk Factors in Northern Han Chinese. Int J Med Sci. The authors genotyped multiple candidate SNPs in RAAS genes and found that rs3889728, together with rs5193 and rs7305099, formed the genetic component of their best-performing diastolic blood pressure prediction model (AUC 0.817). The study does not report allele-specific odds ratios for rs3889728 in isolation, limiting the precision of individual-level risk estimates.

Broader evidence for RAAS gene variants in preeclampsia is substantial. A review of RAAS polymorphisms by Wang et al. 2023⁵⁵ Wang et al. 2023
Pertinence between risk of preeclampsia and RAAS gene polymorphisms. Pregnancy Hypertens found that AGT variants (particularly the 235T allele) and AT1R 1166C are among the most replicated genetic contributors to preeclampsia risk across diverse populations. A separate meta-analysis of 40 studies by Wang et al. 2020⁶⁶ Wang et al. 2020
Three polymorphisms of renin-angiotensin system and preeclampsia risk found AGT T704C (another intronic-region AGT variant) associated with preeclampsia in the dominant model (OR 1.33, 95% CI 1.12–1.59). The fact that multiple intronic and regulatory AGT variants show association with blood pressure outcomes makes it plausible that rs3889728 participates in the same regulatory landscape.

The T allele of rs3889728 is common globally (~25% in Europeans, ~55% in East Asians), making it a variant that tags a common haplotype rather than a rare pathogenic mutation. The evidence level is emerging: the variant is incorporated in one hypertension prediction model, sits in a gene with strong preeclampsia biology, but lacks its own dedicated preeclampsia association study or ClinVar entry.

Practical Actions

For women carrying one or two T alleles, the primary implications are during pregnancy. The RAAS context means that blood pressure monitoring during pregnancy is particularly important — early detection of gestational hypertension allows timely intervention before preeclampsia develops. Low-dose aspirin (81 mg/day from 12–16 weeks) is guideline-recommended for moderate-to-high-risk pregnancies and acts partly by improving placental perfusion and modulating RAAS-mediated vasoconstriction.

Outside pregnancy, the blood pressure relevance of rs3889728 may be modest but meaningful in the context of a RAAS genetic profile. Salt sensitivity and fluid balance are domains where RAAS gene variants cluster — higher sodium intake is associated with greater AGT pathway activation in genetically susceptible individuals.

Interactions

The most relevant interaction is with AT1R rs5186 (A1166C), the angiotensin II type 1 receptor gene variant. AGT produces angiotensin II; AT1R is where angiotensin II acts. Carrying risk alleles in both genes (elevated angiotensin II production from AGT variants and increased receptor sensitivity from AT1R 1166C) compounds the blood pressure effect and has been proposed as a particularly high-risk combination for preeclampsia in several case-control studies. See rs5186 for the AT1R profile. The NPR3 variant rs13154066 affects a complementary vasodilatory pathway (natriuretic peptide clearance); women carrying hypertension-risk alleles in both the RAAS (AGT, AT1R) and natriuretic peptide (NPR3) pathways face convergent pressure toward gestational blood pressure elevation.

Complement factor B (CFB) is the gatekeeping enzyme of the alternative complement pathway — the arm of innate immunity that amplifies inflammatory destruction against pathogens, dead cells, and, in the wrong circumstances, healthy tissue. When factor B binds to C3b¹¹ C3b
the activated form of complement component 3 that acts as an opsonin and amplification hub and forms the C3 convertase complex, it triggers a cascade that deposits inflammatory mediators, recruits immune cells, and, in the retina, damages the delicate photoreceptor support layer. The rs4151667 L9H variant sits in the signal peptide of CFB — the molecular zip code that directs the newly synthesized protein into the secretory pathway — and is one of only two protective non-synonymous variants in the CFB gene with established AMD association. Carriers of the protective A allele have approximately 50% lower odds of developing age-related macular degeneration (AMD), one of the leading causes of irreversible vision loss in adults over 65.

The Mechanism

The L9H substitution (leucine to histidine at position 9) lies within the CFB signal peptide, the short hydrophobic leader sequence encoded by exon 1 that is cleaved co-translationally as the protein enters the endoplasmic reticulum. Signal peptide variants can alter secretion efficiency, folding kinetics, or the quantity of mature protein released into circulation. The functional consequence of L9H has not been fully characterized at the molecular level²² The functional consequence of L9H has not been fully characterized at the molecular level
Gold et al. 2006 acknowledged that direct functional demonstration was lacking but proposed that L9H could modulate CFB secretion and therefore the supply of factor B available for convertase assembly. A plausible model is that the histidine substitution subtly reduces secretion efficiency, producing slightly less circulating factor B — reducing the steady-state availability of the substrate needed for C3 convertase assembly and thereby dampening basal alternative pathway tick-over.

L9H is in nearly complete linkage disequilibrium (LD) with the C2 E318D variant (rs9332739), forming the well-characterized protective haplotype H10. The co-occurrence of these two variants in cis means that the AMD protection attributed to L9H likely reflects the combined effect of reduced CFB secretion efficiency and altered C2 classical pathway activity, and it remains difficult to disentangle the independent contribution of each polymorphism. The functionally better-characterised CFB R32Q variant (rs641153)³³ CFB R32Q variant (rs641153)
a missense variant at codon 32 in the Ba domain; Q32 binds C3b with up to 4× lower affinity than R32, directly reducing C3 convertase formation is on a distinct protective haplotype (H7) in high LD with C2 rs9332739 but not with L9H, and serves as a mechanistic model for how reduced CFB activity protects the complement-vulnerable retinal pigment epithelium.

The Evidence

The initial discovery of CFB L9H as an AMD protective variant came from a 2006 landmark Nature Genetics study by Gold et al.⁴⁴ Nature Genetics study by Gold et al.
Two independent cohorts totalling ~900 AMD cases and ~400 controls; protective haplotype H10 carrying L9H had OR 0.36; standalone L9H had OR 0.45 per allele; combined with CFH variation, 74% of clinical outcomes were explained. Multiple subsequent meta-analyses confirmed the protection. A 2012 HuGE review and meta-analysis by Thakkinstian et al.⁵⁵ 2012 HuGE review and meta-analysis by Thakkinstian et al.
Pooled 19 studies, 2006–2011; rs4151667 A allele OR 0.54 (95% CI 0.45–0.64); absolute AMD risk reduction of 2–6% in Caucasians synthesised the population-level effect. A concurrent Sun et al. systematic review and meta-analysis⁶⁶ Sun et al. systematic review and meta-analysis
15 case-control studies; dominant model pooled OR 0.496 (95% CI 0.390–0.632, P<0.001) in Caucasians; protective effect weaker in Asians (AT/TT OR 0.68) corroborated the finding.

The protective effect is population-dependent: it is most consistently replicated in Europeans, where the A allele frequency is approximately 4–7%, while a negative case-control study in an Iranian cohort (n=407) found no significant association, likely reflecting differences in local LD patterns and haplotype backgrounds. The protective haplotype H10 (L9H + C2 E318D) contributes a 2–6% absolute risk reduction in Caucasian populations — modest in isolation, but large relative effects when AMD baseline risk is stratified by concomitant CFH risk genotype.

Functionally, the best evidence for the mechanism comes from the Heurich et al. 2011 PNAS complotype study⁷⁷ Heurich et al. 2011 PNAS complotype study
showed the full complement of common CFB, C3, and CFH polymorphisms can span a 6-fold range in hemolytic complement activity; the R32Q variant (in LD with the L9H haplotype background) reduces C3b binding affinity up to 4-fold, substantially lowering complement amplification.

Practical Actions

The protective A allele acts as a dampener on the alternative complement pathway. For heterozygous AT carriers, one copy reduces complement-driven drusen formation risk by approximately 40–50% per the population data. Homozygous AA carriers (rare, ~0.2% of Europeans) carry both copies of the protective allele and have the lowest complement-driven AMD risk from this locus.

While no supplement directly substitutes for this genetic protection, several complement pathway nutrients and lifestyle factors modulate AMD risk through overlapping pathways. The AREDS2 clinical trial formula (lutein/zeaxanthin + vitamin C + vitamin E + zinc/copper) is the only nutritional intervention with established AMD risk reduction in high-risk individuals, but its benefit is independent of CFB genotype. For AT and AA carriers, the primary actionable value lies in understanding their reduced genetic AMD risk — a meaningful counterweight to modifiable risk factors like smoking and UV exposure — while still maintaining standard AMD surveillance.

Interactions

rs4151667 is in near-complete LD with the C2 E318D variant (rs9332739), forming the H10 protective haplotype. Individuals carrying the rs4151667 A allele almost always also carry the rs9332739 C allele; the combined AMD protective effect is OR ~0.36 for the full H10 haplotype, stronger than either variant alone. The CFB R32Q variant (rs641153) provides AMD protection through a different mechanism (direct reduction in C3b binding affinity) on the independent H7 haplotype; carriers of both L9H and R32Q are exceptionally rare but would theoretically carry additive complement-dampening effects.

The L9H protective effect is most clinically relevant when assessed in the context of CFH Y402H (rs1061170) and ARMS2/HTRA1 variants — the dominant AMD risk loci. Carriers of the CFH 402H risk allele with CFB L9H protection represent a mixed-risk genetic profile where the classical-pathway (CFH) risk and alternative-pathway (CFB) protection partially offset each other. Formal risk score modelling incorporating CFH, ARMS2, and CFB variants explains the majority of AMD genetic risk in European populations.

Primary open-angle glaucoma (POAG) is the leading cause of irreversible blindness worldwide, affecting over 70 million people¹¹ affecting over 70 million people
Glaucoma is a chronic degenerative optic neuropathy with progressive loss of retinal ganglion cells resulting in characteristic optic nerve cupping and visual field defects. The disease typically progresses silently for years before vision loss becomes noticeable. The rs4236601 variant sits in the regulatory region between the CAV1 and CAV2 genes on chromosome 7q31, and was the first common genetic risk factor identified for POAG through genome-wide association studies²² was the first common genetic risk factor identified for POAG through genome-wide association studies.

The Mechanism

This intergenic variant affects the expression and function of caveolin-1 and caveolin-2, structural proteins that form caveolae — specialized flask-shaped invaginations of the plasma membrane that are abundant in the trabecular meshwork and Schlemm's canal³³ caveolae — specialized flask-shaped invaginations of the plasma membrane that are abundant in the trabecular meshwork and Schlemm's canal
These structures regulate aqueous humor outflow, the drainage system that controls intraocular pressure. The trabecular meshwork is the primary site of resistance to aqueous humor outflow, and dysfunction in this tissue is the hallmark of POAG pathophysiology.

Studies in caveolin-1 knockout mice reveal the functional importance of this protein: Cav-1-deficient mice display ocular hypertension explained by reduced pressure-dependent drainage of aqueous humor⁴⁴ Cav-1-deficient mice display ocular hypertension explained by reduced pressure-dependent drainage of aqueous humor. The loss of caveolae in the trabecular meshwork and Schlemm's canal renders these tissues unable to properly respond to mechanical stress from IOP fluctuations⁵⁵ renders these tissues unable to properly respond to mechanical stress from IOP fluctuations, suggesting that caveolae provide both mechanical buffering and mechanotransduction signaling platforms.

The rs4236601 risk variant may reduce CAV1 expression in relevant ocular tissues. While no correlation was found between rs4236601 and CAV1 expression in blood or adipose tissue⁶⁶ no correlation was found between rs4236601 and CAV1 expression in blood or adipose tissue, gene regulation is highly tissue-specific, and the variant likely affects expression specifically in the trabecular meshwork where it matters most. Some glaucoma-associated CAV1/CAV2 polymorphisms have been shown to reduce caveolin-1 expression in various tissues⁷⁷ reduce caveolin-1 expression in various tissues, supporting the hypothesis that reduced caveolae formation compromises aqueous outflow regulation.

The Evidence

The initial genome-wide association study in 1,263 Icelandic POAG cases and 34,877 controls identified rs4236601[A] with an odds ratio of 1.36 (P = 5.0 × 10⁻¹⁰)⁸⁸ genome-wide association study in 1,263 Icelandic POAG cases and 34,877 controls identified rs4236601[A] with an odds ratio of 1.36 (P = 5.0 × 10⁻¹⁰). The association was replicated in 2,175 European cases (combined OR = 1.18) and 299 Chinese cases (combined OR = 5.42)⁹⁹ replicated in 2,175 European cases (combined OR = 1.18) and 299 Chinese cases (combined OR = 5.42), demonstrating both reproducibility and striking ancestry-specific effect sizes.

The variant shows dramatic frequency differences across populations. In European populations, the A risk allele occurs at 27-29% frequency¹⁰¹⁰ 27-29% frequency, while in Chinese populations it is rare at 0.43-1.3% frequency¹¹¹¹ 0.43-1.3% frequency but carries a much larger effect size (OR = 5.26). This pattern suggests the A allele may be tagging different causal variants in different ancestral backgrounds, or that genetic background modifies penetrance.

Importantly, rs4236601 is also associated with elevated intraocular pressure (IOP) independent of glaucoma diagnosis. The minor allele A is associated with a 0.42 mm Hg increase in mean IOP¹²¹² The minor allele A is associated with a 0.42 mm Hg increase in mean IOP in European populations, and meta-analysis across multiple IOP GWAS studies achieved genome-wide significance (P = 4.0 × 10⁻¹¹)¹³¹³ meta-analysis across multiple IOP GWAS studies achieved genome-wide significance (P = 4.0 × 10⁻¹¹).

Replication studies have yielded mixed results across populations. While US Caucasian studies confirmed the association¹⁴¹⁴ US Caucasian studies confirmed the association, particularly in women, studies in Saudi Arabian¹⁵¹⁵ Saudi Arabian and Brazilian¹⁶¹⁶ Brazilian populations failed to replicate the finding. This heterogeneity may reflect differences in genetic background, linkage disequilibrium patterns, environmental factors, or POAG subtype distributions.

Practical Implications

Elevated IOP is the most important modifiable risk factor for glaucoma progression, and the only treatment target for which we have effective interventions. While rs4236601 genotype is not currently used in clinical decision-making, understanding your genetic risk can inform screening strategies and motivate adherence to regular comprehensive eye examinations.

The American Academy of Ophthalmology recommends comprehensive eye examinations for all adults over age 40¹⁷¹⁷ comprehensive eye examinations for all adults over age 40 to screen for glaucoma. Individuals with the AA genotype, particularly those with additional risk factors (family history, African ancestry, myopia, thin central corneal thickness), may benefit from more frequent screening and earlier initiation of monitoring protocols.

IOP exhibits substantial diurnal variation, with many glaucoma patients experiencing peak pressures in the early morning hours outside of office visit times¹⁸¹⁸ peak pressures in the early morning hours outside of office visit times. Home tonometry devices now enable continuous monitoring that may detect pressure spikes missed by clinic measurements, potentially enabling more personalized treatment approaches.

Interactions

The CAV1/CAV2 locus interacts functionally with the nitric oxide signaling pathway, as caveolin-1 regulates endothelial nitric oxide synthase (eNOS) activity in caveolae. This connection may explain the association between CAV1/CAV2 variants and POAG subtypes characterized by vascular dysregulation¹⁹¹⁹ association between CAV1/CAV2 variants and POAG subtypes characterized by vascular dysregulation, particularly normal-tension glaucoma and cases with paracentral visual field defects. The interaction between ET-1 (endothelin-1), NO, and CAV1 is suspected to underlie aberrant retinal hemodynamic responses to postural changes observed in POAG patients.

Other POAG risk loci include CDKN2B-AS1 (rs2157719), TMCO1 (rs7518099), and SIX1/SIX6 (rs10483727). While no specific gene-gene interactions between rs4236601 and these loci have been definitively established, polygenic risk scores incorporating multiple POAG variants show additive effects on disease risk.

Your kidneys filter roughly 700 mg of uric acid every day and then reabsorb most of it — resetting your blood urate baseline with each filtration cycle. The protein that handles the largest share of that reabsorption is GLUT9¹¹ GLUT9
Glucose Transporter 9, encoded by SLC2A9. Despite its name, GLUT9's dominant physiological role in the adult kidney is voltage-driven urate transport, not glucose, encoded by the SLC2A9 gene on chromosome 4. rs4519796 sits 292 base pairs upstream of a well-characterised intronic SLC2A9 risk variant (rs6814664), in the same intronic region of the gene, and carries an identical population-frequency signature: the A allele is most common in East Asians (~92%), who have the world's highest rates of gout, and least common in Africans (~34%), who historically have had lower gout burden. This gradient is the hallmark of SLC2A9 urate-reabsorption risk haplotypes.

The Mechanism

SLC2A9 encodes two kidney isoforms — GLUT9a on the basolateral membrane of proximal tubule cells, which returns reabsorbed urate to the circulation, and GLUT9b on the apical membrane, which accepts urate from the tubular lumen. Together they form the dominant urate-recapture system: filtered urate enters the lumen, URAT1 shuttles it into the tubular cell, and GLUT9a pumps it back into blood. Variants in the intronic and regulatory regions of SLC2A9 modulate how much GLUT9 is expressed, rather than changing the protein's sequence. Fine-mapping of the SLC2A9 locus²² Fine-mapping of the SLC2A9 locus
Wei et al. Abundant local interactions in the 4p16.1 region. Hum Mol Genet, 2014 has identified multiple independent signals with epistatic interactions, collectively explaining more urate variance than any single SNP. rs4519796 is positioned within this same regulatory window and is a likely tag for haplotypes that increase GLUT9 expression or transport activity, resulting in more urate being retained per filtration cycle.

Because no published study has directly tested rs4519796 in isolation, the evidence for this specific variant rests on its position within the SLC2A9 risk locus and its population frequency gradient — not on a direct genotype-phenotype association study. This places rs4519796 in the emerging evidence tier: the locus effect is established, but this variant's independent contribution has not been formally quantified.

The Evidence

The SLC2A9 locus is the most replicated genetic determinant of serum urate in humans. Vitart et al. (2008)³³ Vitart et al. (2008)
Vitart V et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nature Genetics, 2008 showed that intronic SLC2A9 variants explain 1.7–5.3% of serum urate variance across Croatian, UK, and German samples and associate with reduced fractional excretion of uric acid — confirming that the mechanism is impaired renal clearance, not overproduction.

Döring et al. (2008)⁴⁴ Döring et al. (2008)
Döring A et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nature Genetics, 2008 found that SLC2A9 intronic variants in introns 4 and 6 explain approximately 1.2% of serum urate variance in men and a striking 6% in women. Effect sizes were −0.23 to −0.36 mg/dL per protective allele, with women showing up to twice the effect size of men. SLC2A9 isoform 2 expression explained 3.5% of urate variance in men and 15% in women — likely reflecting estrogen-mediated regulation of GLUT9 in proximal tubule cells.

Across the SLC2A9 locus as a whole, Yang et al. (2010)⁵⁵ Yang et al. (2010)
Yang Q et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet, 2010 confirmed that SLC2A9 and ABCG2 are the only two loci reaching genome-wide significance for gout across 28,283 participants in a multi-cohort meta-analysis, underscoring the transporter axis as the dominant genetic driver of gout susceptibility.

Sex-specific note: The sex-divergent effect of SLC2A9 intronic variants is one of the best-replicated gene-by-sex interactions in metabolic genetics. Women carrying the risk haplotype — who have lower baseline urate than men and therefore face a proportionally larger relative increase — should treat this variant's significance as equivalent to, or greater than, the warning level applied to men with the same genotype.

Practical Actions

The actionable levers for A-allele carriers mirror those for adjacent SLC2A9 variants: reduce the urate substrate that the overactive GLUT9 transporter is positioned to recapture. Organ meats (liver, kidney, sweetbreads) and red meat are the highest-purine dietary sources. Alcohol — especially beer, which combines brewer's yeast purines with ethanol's direct urate-retention effect — is the most potent modifiable trigger. High-fructose intake drives urate synthesis through inosine monophosphate generation and competes with urate for SLC2A9 transport. Low-fat dairy and coffee are associated with lower serum urate in epidemiological data.

The clinical urate crystallisation threshold is 6.8 mg/dL; maintaining serum urate below 6.0 mg/dL is the standard prevention target.

Interactions

With rs6814664 (SLC2A9 intronic, 292 bp downstream): rs6814664 is the nearest characterised SLC2A9 intronic risk variant (C allele = risk) and the two SNPs share the same population frequency gradient. Individuals carrying both A at rs4519796 and C at rs6814664 carry the full SLC2A9 intronic risk haplotype in this region of the gene.

With rs3733591 (SLC2A9 Arg265His missense): rs3733591 is an independent coding variant at SLC2A9 with larger per-allele urate effect (~0.65 mg/dL). A carriers at rs4519796 who also carry C at rs3733591 face additive urate burden from both regulatory and protein-level mechanisms.

With rs2231142 (ABCG2 Q141K): ABCG2 controls intestinal urate excretion while SLC2A9 controls renal reabsorption. A-allele carriers at rs4519796 who also carry the ABCG2 Q141K T allele face elevated urate from two mechanistically independent routes, substantially compounding gout risk.

With BMI: SLC2A9 intronic variant effects on serum urate are amplified at higher BMI — a replicated interaction in two independent cohorts. AA homozygotes who are overweight or obese accumulate a greater urate load than the genotype alone predicts; weight reduction has proportionally greater benefit in this group.

Interferon Regulatory Factor 5 (IRF5) is the molecular ignition switch for the type I interferon response — the branch of innate immunity responsible for fighting viral infections by triggering widespread pro-inflammatory signaling. When IRF5 is overactive, the same cascade that defends against viruses begins attacking the body's own tissues, driving systemic lupus erythematosus (SLE), Sjögren's syndrome, systemic sclerosis, and other autoimmune diseases. rs4728142 sits approximately 5 kilobases upstream of IRF5's transcription start sites, in a region now established as an active enhancer¹¹ active enhancer
An enhancer is a regulatory DNA element that boosts transcription of a nearby gene; it doesn't have to be immediately adjacent — enhancers can act from tens of thousands of base pairs away via DNA looping for the gene. The A allele of rs4728142 has recently been confirmed as the leading causal variant for the 5' IRF5 risk signal — not merely a tag for some other functional change, but the variant that directly rewires how the IRF5 gene is regulated.

The Mechanism

rs4728142 operates through a newly described chromatin-looping mechanism. The A allele alters the binding affinity of ZBTB3 (Zinc Finger and BTB Domain-Containing Protein 3)²² ZBTB3 (Zinc Finger and BTB Domain-Containing Protein 3)
A transcription factor that recognizes specific DNA sequences and can recruit chromatin-remodeling complexes; ZBTB3 belongs to the BTB-POZ family involved in gene regulation and cell fate decisions. When ZBTB3 binds the rs4728142-A allele, it orchestrates a short-range chromatin loop that physically connects the upstream enhancer region to the alternative (short-transcript) promoter of IRF5. The consequence: the IRF5 gene preferentially produces its shorter isoforms at the expense of the full-length transcript, and total IRF5 expression is markedly elevated. In lymphoblastoid cells from European ancestry individuals, the A allele is associated with a 1.5-fold increase in IRF5 mRNA³³ 1.5-fold increase in IRF5 mRNA
Bonferroni-corrected P=0.0004 in CEU cell lines; smaller but significant effects also seen in Asian-ancestry cells (1.2-fold, P=0.006). In SLE patient monocytes, CRISPR-based interference with the enhancer function at this locus attenuated production of lupus-associated cytokines, confirming the causal chain from variant to expression to inflammatory output.

The rs4728142-A allele is in strong linkage disequilibrium⁴⁴ linkage disequilibrium
LD measures how often two nearby variants are inherited together; r²>0.6 means the two variants co-occur on the same chromosome much more often than chance would predict (r²>0.6) with the CGGGG insertion-deletion polymorphism in the IRF5 promoter. The CGGGG indel sits 64 base pairs upstream of the exon 1A transcription start site; the 4-copy insertion allele (4R) creates an additional binding site for the transcription factor Sp1, which was confirmed by electrophoretic mobility shift assays. The 4R allele increases IRF5 mRNA expression in peripheral blood mononuclear cells and amplifies interferon-inducible gene expression (MX1, IFITM1) in Sjögren's patients. rs4728142 and the CGGGG indel together provide complementary molecular explanations for why the 5' region of IRF5 elevates interferon tone: the CGGGG indel creates an extra Sp1 site at the promoter; rs4728142 directs an enhancer loop to that promoter.

The Evidence

The breadth of disease associations for rs4728142 is exceptional even among major autoimmune risk loci. The variant has been independently associated with six autoimmune conditions across multiple populations.

In systemic lupus erythematosus, a large meta-analysis of IRF5 variants across nine populations found rs4728142 among the strongest independent signals P=1.34×10⁻⁸, OR=1.22 (95% CI 1.14–1.30)⁵⁵ P=1.34×10⁻⁸, OR=1.22 (95% CI 1.14–1.30)
Pooled analysis across European, Asian, and admixed populations from multiple case-control studies, placing it among the most replicated non-HLA genetic risk factors for lupus.

In primary Sjögren's syndrome, the CGGGG indel (in LD with rs4728142-A) was found to fully explain the IRF5-Sjögren's association in two independent Norwegian and British cohorts, yielding OR=2.00 (95% CI 1.5–2.7, P=6.6×10⁻⁶)⁶⁶ OR=2.00 (95% CI 1.5–2.7, P=6.6×10⁻⁶)
Norheim et al. 2012, Annals of the Rheumatic Diseases; OR of 2.00 for carrying the 4R CGGGG allele vs the 3R allele. Carriers of the 4R allele had measurably higher IRF5 mRNA in both peripheral blood and salivary gland epithelial cells — the tissue most directly relevant to Sjögren's pathology.

In inflammatory bowel disease, the CGGGG indel was the lead signal in an independent IBD GWAS analysis, with OR=1.81 for overall IBD (P=1.9×10⁻⁵) and OR=2.42 specifically for ulcerative colitis (P=5.3×10⁻⁸)⁷⁷ OR=1.81 for overall IBD (P=1.9×10⁻⁵) and OR=2.42 specifically for ulcerative colitis (P=5.3×10⁻⁸)
Eames et al. 2007, Human Molecular Genetics; replication in a second cohort OR=1.59. The UC association is among the strongest single-gene effects in IBD genetics.

In multiple sclerosis, rs4728142 showed independent association across Spanish, Swedish, and Finnish cohorts (combined P<0.001, OR≈1.14), with allele-specific protein binding on EMSA suggesting direct transcription factor recruitment at the variant site rather than passive LD.

In systemic sclerosis, the three-SNP IRF5 haplotype incorporating rs4728142 reached OR=1.75 (P=9.04×10⁻²²)⁸⁸ OR=1.75 (P=9.04×10⁻²²)
Dieudé et al. 2013, PLOS ONE; five-country European study including Spain, Germany, Netherlands, Italy, and UK, exceeding the effect of rs10488631 alone and confirming additive contributions from the 5' and 3' haplotype blocks.

Practical Implications

The A allele at rs4728142 acts as an immune-system volume dial stuck at a higher setting. The overexpressed IRF5 protein amplifies both the initial interferon alarm response and subsequent pro-inflammatory cytokine cascades (TNF-α, IL-6, IL-12). For most carriers this translates to modest increases in autoimmune disease susceptibility across multiple organ systems — not a predetermined path to disease, but a meaningful shift in the immune threshold.

Because rs4728142 affects the IRF5 enhancer rather than the coding sequence, its effects are partly modifiable by context: the immune system's activation state, the presence of viral triggers (particularly Epstein-Barr virus, strongly implicated in SLE pathogenesis), and environmental modulators of interferon tone including vitamin D. The discovery that CRISPR interference with this enhancer can attenuate lupus-associated cytokine production in patient monocytes indicates that this regulatory region is being studied as a potential therapeutic target.

Population stratification is striking at this locus: European and Latino populations carry the A allele at approximately 44% frequency — nearly half the population — while East Asian populations carry it at only 13%. This mirrors the population-level differences in autoimmune disease prevalence and suggests that variation at IRF5 contributes to the well-documented ethnic disparities in lupus and related conditions.

Interactions

rs4728142 functions within the IRF5 three-block haplotype architecture alongside rs2004640 (exon 1B splice site) and rs10488631 (3' haplotype tag). The 5' block tagged by rs4728142 and the 3' block tagged by rs10488631 operate independently and additively: individuals carrying both the rs4728142-A risk allele and the rs10488631-C risk allele carry contributions from both haplotype blocks, with combined effects substantially exceeding those of either alone. The three-block SSc haplotype data illustrating OR=1.75 for the combined haplotype versus OR=1.63 for rs10488631 alone quantifies this additive contribution.

Downstream of IRF5, STAT4 (rs7574865) amplifies cellular responsiveness to the interferons that IRF5 drives. IRF5 variants increase interferon production; STAT4 variants increase cellular sensitivity to that interferon. Studies in primary Sjögren's syndrome and SLE demonstrate striking additive effects: with all five IRF5 + STAT4 risk alleles, OR for Sjögren's reaches 6.78. rs4728142 risk carriers with concurrent STAT4 rs7574865 risk alleles thus face a compounded immune activation burden — elevated production and elevated responsiveness to what is produced.

The autoimmune pleiotropic nature of rs4728142 — associated with lupus, Sjögren's, IBD, MS, SSc, and RA — means the variant likely exerts a shared molecular mechanism (IRF5 overactivation) that manifests as different diseases depending on which other genetic and environmental factors are present. Individuals carrying this risk allele who develop symptoms in one autoimmune domain should be aware of overlapping risk across organ systems.

Angiotensinogen (AGT) is the essential precursor protein of the renin-angiotensin system (RAS), the body's primary long-term regulator of blood pressure and fluid balance. The kidney enzyme renin cleaves AGT to produce angiotensin I, which is then converted by ACE to angiotensin II¹¹ angiotensin II
the vasoactive peptide that raises blood pressure by constricting blood vessels and signaling the adrenal glands to release aldosterone. The T174M variant (rs4762) is one of two well-studied missense changes in AGT — alongside [M235T (rs699) | the more frequently studied AGT variant, which is in strong linkage disequilibrium with T174M in many populations] — and both have been investigated for decades as candidates for genetically elevated blood pressure.

The Mechanism

AGT sits on the minus strand of chromosome 1 at position 230,710,231 (GRCh38). The rs4762 G>A change on the plus strand produces a Threonine-to-Methionine substitution at position 198 of the angiotensinogen precursor²² Threonine-to-Methionine substitution at position 198 of the angiotensinogen precursor
also described as T174M in older literature counting from the mature protein after signal peptide cleavage. This amino acid change in the AGT protein is thought to affect its rate of cleavage by renin and its plasma concentration³³ plasma concentration
carriers of the A allele tend to have higher circulating angiotensinogen levels, shifting the equilibrium of the entire RAS toward higher angiotensin II output. Higher angiotensin II drives sustained increases in vascular tone, sodium retention, and — over years — contributes to hypertension and end-organ damage.

The Evidence

The AGT gene's role in hypertension was first established in 1992⁴⁴ first established in 1992
Jeunemaitre et al., "Molecular basis of human hypertension: role of angiotensinogen." Cell 71:169-80, when genetic linkage between AGT variants and hypertension was demonstrated in two large independent family panels. This landmark paper showed that AGT molecular variants were inherited predispositions to essential hypertension and that plasma AGT concentrations differed by genotype.

The cardiovascular consequences of rs4762 were quantified in a 2021 meta-analysis of 7,657 subjects across 11 studies⁵⁵ 2021 meta-analysis of 7,657 subjects across 11 studies
Li et al., "Myocardial Infarction and AGT p.Thr174Met Polymorphism: A Meta-Analysis of 7657 Subjects." Cardiovascular Therapeutics 2021. The A (Met174) allele significantly increased myocardial infarction risk: OR 2.26 (95% CI 1.35–3.77) under the recessive model, OR 1.13 (95% CI 1.02–1.26) under the dominant model, and OR 1.36 (95% CI 1.13–1.64) under the additive model. Effects were strongest in Asian populations; Caucasian subgroup analyses did not reach statistical significance.

Park et al. 2013⁶⁶ Park et al. 2013
"Assessment of two missense polymorphisms (rs4762 and rs699) of the angiotensinogen gene and stroke." Experimental and Therapeutic Medicine 5:343-349 examined 197 stroke patients and 301 controls, finding that the rs4762 A (T allele on coding strand) allele was associated with [intracerebral hemorrhage | 16.2% allele frequency in ICH vs 9.6% in controls, P=0.021] and correlated with worse neurological severity scores. Ischemic stroke was not significantly associated.

In a Mexican cohort of 546 adults with diabetic nephropathy, Vázquez-Moreno et al. 2021⁷⁷ Vázquez-Moreno et al. 2021
"AGT rs4762 is associated with diastolic blood pressure in Mexicans with diabetic nephropathy." Journal of Diabetes and Its Complications 35(3) found that the A allele predicted higher diastolic blood pressure specifically in those with established kidney disease (β=2.84, P=0.026), an important finding because diastolic hypertension drives progression of diabetic nephropathy.

A 2018 study in Han Chinese women⁸⁸ 2018 study in Han Chinese women
Zhou et al., Biomed Res Int 2018, n=156 preeclampsia / 286 controls identified rs4762 as one of seven alleles significantly associated with preeclampsia susceptibility. Notably, a large 2016 meta-analysis of 95 case-control studies⁹⁹ 2016 meta-analysis of 95 case-control studies
Zhang et al., Medical Science Monitor, n=16,646 PE patients / 28,901 controls found no overall significant association of rs4762 with preeclampsia across all ancestries combined, suggesting population-specific effects — consistent with the pattern seen for MI risk.

Practical Implications

The A allele raises circulating angiotensinogen and tips the RAS toward sustained vasoconstriction. For carriers, this is not destiny — the RAS is highly modifiable by both lifestyle and medication. RAS-targeting medications (ACE inhibitors, ARBs) act downstream of AGT and are among the most effective antihypertensives available. Dietary sodium directly amplifies RAS activation: each gram of excess sodium per day substantially raises angiotensin II-driven pressure in those with genetically elevated AGT. Conversely, [low-sodium dietary patterns | below 2,300 mg/day, or ideally 1,500 mg/day for those at elevated cardiovascular risk] are among the most potent non-pharmacological strategies for blunting AGT-mediated pressure elevation.

Interactions

rs4762 is in linkage disequilibrium with rs699 (M235T)¹⁰¹⁰ linkage disequilibrium with rs699 (M235T)
the two variants are often co-inherited and studied as a haplotype block. Haplotype analyses consistently show stronger associations with blood pressure and cardiovascular disease than either SNP alone. The AGT gene also interacts with [rs5186 (AGTR1 A1166C) | the angiotensin II type 1 receptor variant] — when both the AGT signal peptide and the AT1 receptor are variant, the downstream pressor response is amplified. In women, AGT haplotypes interact significantly with hypertension status to modulate coronary artery disease risk, a gene-environment interaction that may partly explain sex-specific cardiovascular risk patterns.

Iron deficiency is the world's most common nutritional deficiency, yet how much iron your gut actually absorbs is controlled less by what you eat and more by a hormone called hepcidin¹¹ hepcidin
A 25-amino-acid peptide produced by the liver that acts as the master regulator of systemic iron homeostasis; high hepcidin blocks iron absorption and recycling. The TMPRSS6 gene encodes matriptase-2²² matriptase-2
A type II transmembrane serine protease expressed primarily in the liver that cleaves hemojuvelin, suppressing hepcidin production, whose job is to keep hepcidin in check by cleaving a cell-surface protein called hemojuvelin³³ hemojuvelin
A co-receptor for bone morphogenetic proteins (BMPs) that, when intact on the hepatocyte surface, drives hepcidin gene transcription. The rs4820268 variant — a single nucleotide change in the protein-coding sequence of TMPRSS6 — alters one amino acid in matriptase-2 and shifts the setpoint of this hormonal control system, with measurable consequences for iron status that play out across the lifespan.

The Mechanism

The A allele of rs4820268 changes aspartic acid to glutamic acid at position 512 of the matriptase-2 protein (p.Asp512Glu). This substitution falls within the functional region of the enzyme and impairs its ability to suppress hepcidin production. With less matriptase-2 activity, hemojuvelin remains intact on hepatocyte surfaces, activating the BMP/SMAD signaling pathway⁴⁴ BMP/SMAD signaling pathway
Bone morphogenetic protein/SMAD — a signaling cascade that drives transcription of the hepcidin gene HAMP in liver cells and sustaining elevated hepcidin levels. Higher hepcidin causes ferroportin⁵⁵ ferroportin
The only known mammalian iron exporter, expressed on gut enterocytes, macrophages, and hepatocytes; hepcidin binds ferroportin, triggers its internalization and degradation, blocking cellular iron export degradation in gut enterocytes, reducing the amount of dietary iron that crosses from gut lining into blood.

The effect is additive: each additional A allele incrementally reduces matriptase-2 activity, raises hepcidin, and lowers net iron absorption. The GG genotype (no amino acid change, synonymous) represents wild-type enzyme function.

The Evidence

A 2025 systematic review⁶⁶ 2025 systematic review
Fauzan R et al. Impact of TMPRSS6 Genetic Variants on Maternal Iron Status in Pregnancy: A Systematic Review. Birth Defects Research, 2025 of seven studies encompassing 1,094 pregnant participants found that the A allele consistently correlated with lower serum iron, reduced transferrin saturation, and elevated unsaturated iron-binding capacity. The review further identified associations with increased risks of iron-deficiency anemia, gestational diabetes mellitus, and preeclampsia — outcomes mediated through impaired iron absorption and downstream metabolic disturbances.

A recall-by-genotype study⁷⁷ recall-by-genotype study
Jallow MW et al. Common Variants in the TMPRSS6 Gene Alter Hepcidin but not Plasma Iron in Response to Oral Iron in Healthy Gambian Adults. Current Developments in Nutrition, 2021 in 251 adults directly confirmed the hepcidin mechanism: AA homozygotes had baseline hepcidin of 9.50 ng/mL compared to 3.27 ng/mL in GG homozygotes (P = 0.002) — nearly a three-fold difference. This study also found that after a large oral iron dose (130 mg elemental iron), TMPRSS6 genotype altered the hepcidin response but did not fully overcome the absorption disadvantage.

An Egyptian study of 160 children (Hamed et al. 2024⁸⁸ Hamed et al. 2024
Hamed HM et al. The association of TMPRSS6 gene polymorphism with iron status in Egyptian children. BMC Pediatrics, 2024) found the GG genotype was linked to the highest hepcidin gene expression, lowest serum ferroportin, and lowest iron stores, confirming that the G allele (without the Asp512Glu change) confers the greatest risk in this specific direction in some ancestry contexts — underscoring the importance of considering both variants and population context together.

A Chinese Han study of 1,574 adults (Gan et al. 2012⁹⁹ Gan et al. 2012
Gan W et al. Association of TMPRSS6 polymorphisms with ferritin, hemoglobin, and type 2 diabetes risk in a Chinese Han population. AJCN, 2012) found rs4820268 significantly associated with plasma ferritin (P ≤ 0.006), hemoglobin (P ≤ 0.001), and iron overload risk (P ≤ 0.007), also detecting a link to type 2 diabetes risk (P ≤ 0.031) — likely mediated through iron's role in insulin signaling.

Practical Implications

For most people with adequate dietary iron and normal iron demand, even the AA genotype does not guarantee iron deficiency — the body's iron regulatory system has multiple compensatory mechanisms. The risk becomes clinically meaningful when demand increases (menstruation, pregnancy, adolescent growth) or intake is marginal (plant-based diets, food insecurity, malabsorption). In these contexts, impaired matriptase-2 function can tip the balance toward depleted iron stores faster than average.

Practical strategies to compensate: pair non-heme iron sources with vitamin C (which reduces ferric to ferrous iron and forms a soluble chelate resistant to hepcidin-mediated inhibition); prefer heme iron (meat, organ meats, shellfish) where possible — heme iron enters enterocytes via HCP1 rather than through ferroportin, making it less sensitive to elevated hepcidin; avoid tea, coffee, and calcium supplements within 60 minutes of iron-rich meals. For supplementation, iron bisglycinate is partially absorbed via peptide transporters, offering a partial bypass of the hepcidin-ferroportin bottleneck.

Serum ferritin is the most sensitive early marker of iron depletion; it falls before hemoglobin drops, allowing intervention before anemia develops.

Interactions

rs4820268 is in linkage disequilibrium with rs855791 — the other major TMPRSS6 coding variant (Ala736Val) — and the two together explain more variance in iron status than either alone. Carriers of risk alleles at both loci have compounded impairment of matriptase-2 function. In the context of hereditary hemochromatosis (HFE C282Y or H63D variants, rs1800562 or rs1799945), TMPRSS6 risk alleles may partially counteract the pathological iron overload driven by reduced hepcidin from HFE mutations — the same hepcidin-raising effect that impairs absorption in healthy people acts as a modest brake on iron loading in hemochromatosis carriers.